| Multiple Sclerosis, Secondary Progressive
Kesimpta vs Vumerity
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Kesimpta vs Vumerity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVumerity has a higher rate of injection site reactions vs Kesimpta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vumerity but not Kesimpta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kesimpta
Vumerity
At A Glance
SC injection
Once monthly
Anti-CD20 monoclonal antibody
Oral
Twice daily
Nrf2 pathway activator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 20 mg SC injection at Weeks 0, 1, and 2 (loading doses), then 20 mg SC once monthly starting at Week 4.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 231 mg twice daily orally for 7 days; maintenance dose 462 mg (two 231 mg capsules) twice daily orally; temporary reduction to 231 mg twice daily may be considered for tolerability, resuming 462 mg twice daily within 4 weeks.
Contraindications
- Active HBV infection
- History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA, including anaphylaxis and angioedema
- Known hypersensitivity to diroximel fumarate, dimethyl fumarate, or any excipient of VUMERITY (reactions may include anaphylaxis and angioedema)
- Concomitant use of dimethyl fumarate
Adverse Reactions
Most common (>10%) upper respiratory tract infections, injection-related reactions (systemic), headache, injection-site reactions (local)
Serious infections, injection-related reactions and hypersensitivity reactions, reduction in immunoglobulins, liver injury
Postmarketing hypersensitivity reactions, liver injury
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury, serious gastrointestinal reactions
Postmarketing Acute pancreatitis, gastrointestinal perforation/ulceration/obstruction/hemorrhage, liver function abnormalities (transaminases >=3 times ULN with total bilirubin >2 times ULN), herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Ofatumumab is a recombinant human IgG1 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism in multiple sclerosis is unknown but is presumed to involve B-lymphocyte depletion.
Diroximel fumarate is a prodrug converted to its active metabolite monomethyl fumarate (MMF), which activates the Nrf2 pathway involved in cellular response to oxidative stress and acts as a nicotinic acid receptor agonist in vitro; the mechanism by which it exerts therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kesimpta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Vumerity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Kesimpta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Vumerity
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kesimpta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Vumerity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KesimptaView full Kesimpta profile
VumerityView full Vumerity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.